NPP4 Modulation for Bleeding and Thrombosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods for modulating bleeding and coagulation, particularly in conditions such as bleeding disorders and thrombosis, where the role of NPP enzymes like NPP4 in hemostasis and coagulation is not fully understood and their precise function in thrombosis is uncertain.
Innovation Solution
The development of compositions and methods involving NPP4 polypeptides, fragments, derivatives, and activators or inhibitors to modulate the activity or expression of NPP4, which are administered to treat bleeding disorders, coagulopathy, or thrombosis by promoting or inhibiting platelet degranulation and coagulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NPP4 activity is enhanced to treat bleeding disorders, then coagulation is improved, but thrombosis risk increases
Solution Approach 1:
The patent employs dynamic modulation of NPP4 activity through conditionally activated prodrugs that convert to active forms only under specific pathological conditions (bleeding vs. thrombosis). This allows the system to adapt its coagulation-promoting activity based on the physiological state, enhancing bleeding treatment while minimizing thrombosis risk through spatial and temporal control of enzyme activation.
Solution Approach 2:
The invention achieves local differentiation of NPP4 activity by using tissue-specific promoters and conditionally activated prodrugs that convert to active forms only in bleeding sites. This localized activation ensures coagulation enhancement occurs precisely where needed (bleeding vessels) rather than systemically, thereby treating bleeding disorders while avoiding widespread thrombosis risk.
2Object-affected harmful factors
If NPP4 activity is inhibited to prevent thrombosis, then thrombosis risk is reduced, but coagulation effectiveness decreases
Solution Approach 1:
The patent employs dynamic modulation of NPP4 activity through conditionally activated prodrugs that convert to active forms only under specific pathological conditions (bleeding vs. thrombosis). This allows the system to adapt its coagulation-promoting activity based on the physiological state, enhancing bleeding treatment while minimizing thrombosis risk through spatial and temporal control of enzyme activation.
Solution Approach 2:
The invention achieves local differentiation of NPP4 activity by using tissue-specific promoters and conditionally activated prodrugs that convert to active forms only in bleeding sites. This localized activation ensures coagulation enhancement occurs precisely where needed (bleeding vessels) rather than systemically, thereby treating bleeding disorders while avoiding widespread thrombosis risk.
3Reliability
If existing coagulation treatments are used, then bleeding is controlled, but precision in modulating coagulation processes is insufficient
Solution Approach 1:
The patent segments the coagulation modulation function into distinct molecular components: NPP4 enzyme, conditionally activated prodrugs, and tissue-specific promoters. This segmentation allows independent optimization of each component's function and enables precise control over where and when coagulation enhancement occurs, achieving high precision in targeting bleeding sites while sparing normal vasculature.
Solution Approach 2:
The invention introduces conditionally activated prodrugs as intermediary molecules that bridge the gap between systemic administration and localized action. These prodrugs circulate systemically but convert to active NPP4 enzyme only under specific pathological conditions (bleeding), providing a precise mechanism for spatial and temporal control of coagulation enhancement without requiring direct local application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These approaches effectively treat bleeding disorders by enhancing coagulation and prevent thrombosis by regulating NPP4 activity, addressing the limitations of existing treatments by providing targeted modulation of coagulation processes.
Implementation Method 1
NPPs are cell surface enzymes... that hydrolyze phosphodiester bonds... A subset of the family (NPP1-3) can recognize 5′ nucleotide-containing substrates and, approximately 10 years ago, were also reported to hydrolyze diadenosine polyphosphates, including Ap3A and Ap4A, into AMP and related products
Implementation Method 2
ADP binding to purinergic receptors on the platelet surface (P2Y1, and P2Y12), induces rapid calcium influx and mobilization resulting in platelet shape change, activation and partial degranulation thus promoting platelet aggregation
Implementation Method 3
The first step in thrombus formation consists of platelet adhesion to the exposed subendothelial extracellular matrix at the site of vascular injury... triggering inside-out activation of other surface integrins and the release of platelet granule contents into the extracellular space
Data Source
AI summary
The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of ENPP4.